FDA Acceptance of Linaclotide ANDA Submission by Actavis Labs
The FDA has accepted the ANDA submission for Linaclotide by Actavis Labs.
Published: July 19, 2026
Updated: July 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Gastroenterology / Linaclotide
Company: Actavis Labs
Asset: Linaclotide
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Actavis Labs
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of Actavis Labs' ANDA submission for Linaclotide is a significant regulatory milestone that could alter competitive dynamics in the gastroenterology market. Portfolio teams must evaluate the implications for pricing and market share among existing Linaclotide products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for FDA review and potential approval outcomes for Actavis Labs' Linaclotide.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.